203 results on '"Krähling, Verena"'
Search Results
2. Novel proteolytic activation of Ebolavirus glycoprotein GP by TMPRSS2 and cathepsin L at an uncharted position can compensate for furin cleavage
3. Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine
4. BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19
5. Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome
6. Induction of robust cellular and humoral immunity against SARS-CoV-2 after a third dose of BNT162b2 vaccine in previously unresponsive older adults
7. Quantitative assay to analyze neutralization and inhibition of authentic Middle East respiratory syndrome coronavirus
8. The sphingosine kinase 1 activator, K6PC-5, attenuates Ebola virus infection
9. Longitudinal antibody and T cell responses in Ebola virus disease survivors and contacts: an observational cohort study
10. Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial
11. 2343. SARS-CoV-2 Spike Conformation Essentially Influences Vaccine Immunogenicity – Results from Two Clinical Phase I Trials of the Vector Vaccine Candidates MVA-SARS-2-S and MVA-SARS-2-ST
12. SARS-CoV-2 and Epstein–Barr Virus-like Particles Associate and Fuse with Extracellular Vesicles in Virus Neutralization Tests
13. Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study
14. Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV
15. Adjuvant formulated virus-like particles expressing native-like forms of the Lassa virus envelope surface glycoprotein are immunogenic and induce antibodies with broadly neutralizing activity
16. Development of a Cost-effective Ovine Polyclonal Antibody-Based Product, EBOTAb, to Treat Ebola Virus Infection
17. Self-amplifying RNA vaccine protects mice against lethal Ebola virus infection
18. Ebola Virus Activates IRE1α-Dependent XBP1u Splicing
19. Generation of therapeutic antisera for emerging viral infections
20. Development of an antibody capture ELISA using inactivated Ebola Zaire Makona virus
21. Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine
22. Structural dissection of Ebola virus and its assembly determinants using cryo-electron tomography
23. Dynamics of humoral and T-cell immunity after three BNT162b2 vaccinations in adults older than 80 years
24. Quantitation of SARS-CoV-2 neutralizing antibodies with a virus-free, authentic test
25. Protective CD8+ T Cell Response Induced by Modified Vaccinia Virus Ankara Delivering Ebola Virus Nucleoprotein
26. Recombinant Marburg Virus Expressing EGFP Allows Rapid Screening of Virus Growth and Real-time Visualization of Virus Spread
27. Differential durability of humoral and T cell immunity after two and three BNT162b2 vaccinations in adults aged >80 years
28. Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome
29. Quantitation of SARS-CoV-2 neutralizing antibodies with a virus-free, authentic test
30. A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA
31. Ebola Virus Activates IRE1α-Dependent XBP1u Splicing.
32. Investigating the zoonotic origin of the West African Ebola epidemic
33. Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection
34. Differentially conserved amino acid positions may reflect differences in SARS-CoV-2 and SARS-CoV behaviour
35. Intranasal administration of a monoclonal neutralizing antibody protects mice against SARS-CoV-2 infection
36. Development and characterization of an indirect ELISA to detect SARS-CoV-2 spike protein-specific antibodies
37. Epitopes of naturally acquired and vaccine‐induced anti‐ebola virus glycoprotein antibodies in single amino acid resolution
38. Safety and immunogenicity of rVSV[DELTA]G-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial
39. SARS-CoV-2 and SARS-CoV differ in their cell tropism and drug sensitivity profiles
40. Differentially conserved amino acid positions may reflect differences in SARS-CoV-2 and SARS-CoV behaviour
41. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients
42. Epitopes of Naturally Acquired and Vaccine‐Induced Anti‐Ebola Virus Glycoprotein Antibodies in Single Amino Acid Resolution
43. Epidemiological study to detect active SARS-CoV-2 infections and seropositive persons in a selected cohort of employees in the Frankfurt am Main metropolitan area
44. SARS-CoV-2 and SARS-CoV differ in their cell tropism and drug sensitivity profiles
45. Serine-Arginine Protein Kinase 1 Regulates Ebola Virus Transcription
46. The Sphingosine Kinase-1 Activator, K6PC-5, Attenuates the Ebola Virus Infection and the Virus Induced Cell Death
47. Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study
48. Randomized, Blinded, Dose-Ranging Trial of an Ebola Virus Glycoprotein Nanoparticle Vaccine With Matrix-M Adjuvant in Healthy Adults
49. Serine-arginine protein kinase 1 regulates Ebola virus transcription
50. Tetherin Inhibits Nipah Virus but Not Ebola Virus Replication in Fruit Bat Cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.